Across TCGA pan-cancer cohorts, PDIA2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PDIA2 data layer compared with 26 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher PDIA2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PDIA2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

LSCC, LUAD, and GBM are the cancer types where PDIA2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Tertile	II,III,IV	0.889	0.432	.018	17	view →
LUAD	OS	Tertile	II,III,IV	0.485	0.940	.049	2	view →
GBM	OS	Quartile	All	0.913	0.792	.033	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: PDIA2 tumor-vs-normal RNA expression · all PDIA2 data types